341 related articles for article (PubMed ID: 27447404)
1. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
El Cheikh J; Massoud R; Haffar B; Fares E; Mahfouz R; Jisr T; Kharfan-Dabaja MA; Mougharbel A; Youssef A; Bazarbachi A; Ibrahim A
Leuk Lymphoma; 2017 Nov; 58(11):2745-2747. PubMed ID: 28351183
[No Abstract] [Full Text] [Related]
5. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
6. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):13-5. PubMed ID: 27007006
[No Abstract] [Full Text] [Related]
8. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S
Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648
[No Abstract] [Full Text] [Related]
9. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
Zagadailov EA; Corman S; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Bröckelmann PJ; Illidge T
Leuk Lymphoma; 2018 Jun; 59(6):1413-1419. PubMed ID: 29045163
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
Vinti L; Pagliara D; Buffardi S; Di Ruscio V; Stocchi F; Mariggiò E; Parasole R; Di Matteo A; Petruzziello F; Paganelli V; De Vito R; Del Bufalo F; Strocchio L; Locatelli F
Pediatr Blood Cancer; 2022 Apr; 69(4):e29557. PubMed ID: 35107876
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
Kaloyannidis P; Al Zayer M; Al Darweesh M; Al Batran M; Al Garni A; Al Naim A; Al Hashmi H; Kanfar S
Leuk Lymphoma; 2023 Mar; 64(3):742-745. PubMed ID: 36628991
[No Abstract] [Full Text] [Related]
12. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
Iannitto E; Romano A; Scalzulli PR; Bonanno V; Scalone R; Chiarenza A; Pirosa MC; Caruso AL; Minoia C; Mantuano S; De Santis G; Salerno M; Crescimanno A; Porretto F; Li Gioi F; Ricciuti G; Greco A; Pavone E; Guarini A; Tarantini G; Mannina D; Consoli U; Cascavilla N; Di Raimondo F; Musso M
Eur J Haematol; 2020 Jun; 104(6):581-587. PubMed ID: 32107795
[TBL] [Abstract][Full Text] [Related]
13. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
Chen R; Palmer JM; Thomas SH; Tsai NC; Farol L; Nademanee A; Forman SJ; Gopal AK
Blood; 2012 Jun; 119(26):6379-81. PubMed ID: 22611160
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088
[TBL] [Abstract][Full Text] [Related]
17. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ; Hamlin PA; Perales MA; Gerecitano J; Horwitz SM; Matasar MJ; Noy A; Palomba ML; Portlock CS; Straus DJ; Graustein T; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2013 Feb; 31(4):456-60. PubMed ID: 23248254
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
[TBL] [Abstract][Full Text] [Related]
20. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
